cp-778875

CP‑778875 is a potent and selective small molecule agonist of peroxisome proliferator‑activated receptor alpha (PPARα), developed by Pfizer for the treatment of dyslipidemia and type 2 diabetes mellitus. It was investigated in clinical trials up to phase II for its effects on lipid profiles, particularly HDL-C levels, in subjects with abnormal lipid levels and type 2 diabetes. The drug acts by activating PPARα, a nuclear receptor involved in the regulation of lipid metabolism and fatty acid oxidation. Clinical studies also explored its pharmacokinetic interactions with atorvastatin. Despite initial promise as a PPARα agonist with higher potency than fenofibrate, development was discontinued before approval[1][3][5][6].

Other names

5-(N-(4-((4-ethylbenzyl)thio)phenyl)sulfamoyl)-2-methylbenzoic acidBenzoic acid, 5-(((4-(((4-ethylphenyl)methyl)thio)phenyl)amino)sulfonyl)-2-methyl-